You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel liver fibrosis test for early detection and classification

    SBC: IMMUNOTOPE, INC.            Topic: NIAAA

    DESCRIPTION (provided by applicant): The overall goal of this application is to develop and validate a potential biomarker based assay to determine if it can be used as a noninvasive test to detect the stage of hepatic fibrosis and to predict fibrosis progression in HIV/HCV co-infected patients. Significant fibrosis and cirrhosis are premalignant conditions that greatly increase the risk of the de ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Nomethiazoles Harnessing GABA and NO mimetic activity for Alzheimer's therapy

    SBC: sGC Pharma Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) occurs in one out of eight Americans of age 65 and affects 43% of the elderly over 85. Current FDA-approved drugs only provide symptomatic relief of AD. There is a pressing need to discover newdisease-modifying medications. AD is multifactorial in origin and progression. A drug attenuating several underlying factors is a preferred ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel Insulin Pathway Agonist for Alzheimer's Disease

    SBC: MEDCHEM PARTNERS LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Even though the association of -amyloid peptide (A ) deposition and Alzheimer's Disease (AD) underpins the major hypothesis for disease progression and possibly causation and several drugs addressing the formation or removal of -amyloid plaques have entered clinical trials, no effective therapy exists to date for AD. This reality calls for new targets th ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. A Diarylheptanoid Scaffold to Treat Taopathies

    SBC: ALS BIOPHARMA, LLC            Topic: NIA

    DESCRIPTION: We identified the Myrica cerifera (Southern Bayberry) extract using a systematic screen as a potent reducer of the structural protein tau, which accumulates in a group of diseases called the tauopathies . The most prevalent tauopathy is Alzheimer's disease, for which there is renewed interest in the identification of tau- based therapeutic approaches to treat this devastating d ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. DC-SIGN Inhibitors for the Treatment of HIV Infection

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): DC-SIGN (dendritic cell specific ICAM-3-grabbing non-integrin), a membrane protein of C-type lectin family, is found in high levels on monocyte-derived DCs, some macrophages, and activated B cells. In vivo, DC-SIGN- positive cells were demonstrated in lymph nodes, tonsils, skin, and the subepithelial region of the cervix. DC- SIGN has been shown to bind to a nu ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. New therapeutics for the treatment of Acinetobactor baumannii infections.

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Acinetobacter are strictly aerobic, non-fermentative Gram-negative bacilli that are of major concern in human health, in particular the species Acinetobacter baumannii. They are responsible for clinically important infections that cause a wide variety of maladies including pneumonia, skin and wound infections, bacteremia and meningitis. In addition, A. baumanni ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): In the United States, around 76,250 new cases of melanoma and 9,180 melanoma-related deaths are predicted for 2012. With the therapeutic options currently available, metastatic melanoma patients face the bleak prospectof at best, 10 month's survival and a one-in-ten chance of surviving for 10 years. Surgery and radiation therapy are the mainstay of treatme ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Polaris Oncology Survivor Transition (POST) System

    SBC: POLARIS HEALTH DIRECTIONS, INC            Topic: NCI

    DESCRIPTION (provided by applicant): The Institute of Medicine (IOM) strongly recommends that all breast cancer patients who are ending active treatment have a survivorship plan. Such a plan should assist patients in moving back to their primary care physician (PCP), provide advice for reducing risk for cancer recurrence or new cancer development, and address the remaining psychosocial challenge ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Inhibitors of IgH Gene Enhancers for the Treatment of Multiple Myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: NCI

    DESCRIPTION (provided by applicant): Multiple Myeloma (MM) is a deadly plasma cell malignancy. Treatment advances have improved clinical outcomes over the past decade, but the disease remains incurable, thus creating a need for new and innovative treatmentoptions. The MM drug pipeline includes several proteasome inhibitors and immunomodulatory agents, and other classes of agents that target signal ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Technology-enabled Type 1 Diabetes Education and Support (T1DES)System

    SBC: POLARIS HEALTH DIRECTIONS, INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Management of Type 1 diabetes requires vigilant monitoring by patients who often encounter numerous barriers that can impede proper management. Barriers can include educational, psychosocial, and support issues. PolarisHealth Directions, a small business, and University of Pennsylvania School of Nursing have partnered to develop the Technology-enabled Type 1 Di ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government